{"entity":{"id":"keunchil-park","kind":"person","name":"Keunchil Park","aka":[],"tldr":"Korean lung cancer specialist who led CHRYSALIS, the first human study of amivantamab, whose exon 20 insertion cohort earned the drug its first approval.","summary":"Keunchil Park is a thoracic medical oncologist at Samsung Medical Center in Seoul. He was first author of the 2021 Journal of Clinical Oncology report of the CHRYSALIS study, which showed that the EGFR-MET bispecific antibody amivantamab produced durable responses in EGFR exon 20 insertion non-small-cell lung cancer after platinum chemotherapy, the basis of the drug's first approval. He has led many EGFR-directed lung cancer trials in Asia.","asOf":"2026-09-18","links":[],"tags":["lung","targeted-therapy","trialist"],"related":[],"cancers":["egfr-mutant-nsclc","nsclc","lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":["chrysalis"],"people":[],"bottlenecks":[],"keyPapers":["paper-keunchil-park-lancet-2017","paper-keunchil-park-lancet-2016","paper-keunchil-park-n-engl-j-med-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist and trial lead, Samsung Medical Center, Seoul","institutionId":"samsung-medical-center","specialisms":["EGFR-mutant lung cancer","Bispecific antibodies","Early-phase trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%5BAuthor%5D"}],"papers":[{"title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","journal":"The Lancet","year":2017,"url":"https://doi.org/10.1016/s0140-6736(16)32517-x","doi":"10.1016/s0140-6736(16)32517-x","note":"Europe PMC author record matched by affiliation (Samsung Medical Center); 3857 citations on Europe PMC."},{"title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","journal":"The Lancet","year":2016,"url":"https://doi.org/10.1016/s0140-6736(16)00587-0","doi":"10.1016/s0140-6736(16)00587-0","note":"Europe PMC author record matched by affiliation (Samsung Medical Center); 2326 citations on Europe PMC."},{"title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/nejmoa1910231","doi":"10.1056/nejmoa1910231","note":"Europe PMC author record matched by affiliation (Samsung Medical Center); 2265 citations on Europe PMC."}],"orcid":"0000-0002-4846-7449"},"route":"/people/keunchil-park/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"institution":[{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","route":"/institutions/samsung-medical-center/"}],"trial":[{"id":"chrysalis","kind":"trial","name":"CHRYSALIS","route":"/trials/chrysalis/"}],"paper":[{"id":"paper-keunchil-park-lancet-2016","kind":"paper","name":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","route":"/key-papers/paper-keunchil-park-lancet-2016/"},{"id":"paper-keunchil-park-lancet-2017","kind":"paper","name":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","route":"/key-papers/paper-keunchil-park-lancet-2017/"},{"id":"paper-keunchil-park-n-engl-j-med-2019","kind":"paper","name":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keunchil-park-n-engl-j-med-2019/"}]}}